Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$76 Mln
Revenue (TTM)
$28 Mln
Net Profit (TTM)
$-15 Mln
ROE
-1.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
4.6
Industry P/E
--
EV/EBITDA
139.3
Div. Yield
0 %
Debt to Equity
0.1
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
28,358,700
CFO
$-108.19 Mln
EBITDA
$-77.25 Mln
Net Profit
$-94.98 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Biofrontera AG - ADR
| -34.7 | -16.0 | -32.0 | -63.0 | -48.6 | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
|---|---|
|
Biofrontera AG - ADR
| -59.3 |
|
S&P Small-Cap 600
| 25.3 |
|
BSE Sensex
| 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage... to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany. Read more
Co-Founder & CEO
Dr. Hermann Lubbert Ph.D.
Co-Founder & CEO
Dr. Hermann Lubbert Ph.D.
Headquarters
Leverkusen
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Biofrontera AG - ADR is $1.94 (NASDAQ) as of 06-May-2022 09:30 EDT. Biofrontera AG - ADR has given a return of -48.64% in the last 3 years.
Since, TTM earnings of Biofrontera AG - ADR is negative, P/E ratio is not available.
The P/B ratio of Biofrontera AG - ADR is 4.62 times as on 06-May-2022, a 12 premium to its peers’ median range of 4.12 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
|
2016
|
--
|
--
|
The 52-week high and low of Biofrontera AG - ADR are Rs -- and Rs -- as of 04-Apr-2026.
Biofrontera AG - ADR has a market capitalisation of $ 76 Mln as on 06-May-2022. As per SEBI classification, it is a Small Cap company.
Before investing in Biofrontera AG - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.11
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.